AbCellera to Release Phase 2 Results for ABCL635 on Aug. 10

By Philip Seaworth • Saturday, August 08 16:02 • Permanent Link

AbCellera will report top-line results from its phase 2 trial of ABCL635 on Aug. 10, giving investors their first look at data from a study that enrolled about 80 postmenopausal women with moderate-to-severe vasomotor symptoms linked to menopause.

The company said the trial is designed to measure whether ABCL635 can reduce both the frequency and severity of hot flashes. ABCL635 entered the clinic in July 2025, making this the first program from AbCellera’s GPCR and ion channel platform to reach the pipeline stage.

The announcement comes with a management conference call scheduled for 4:30 a.m. Pacific time, 7:30 a.m. Eastern time, the same day the data are released. The market has reacted to these announcements by moving the company's shares 6.13% to a price of $6.93. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.